BIOQUELL Worldwide
IN THE NEWS
Directors' Dealings - Purchase of Shares
Appointment of Sir Ian Carruthers OBE as a Non-Executive Director Bioquell PLC – 2010 interim results Results of Bioquell PLC AGM Interim Management Statement Annual Report 2009 Press Release Notice of Annual General Meeting 2010 and form of Proxy BIOQUELL delivers strong growth in revenues and profit in 2009 Interim Management Statement Notification of major interest BIOQUELL PLC - Sale of Shares Award by the NHS Purchasing and Supply Agency to BIOQUELL BIOQUELL PLC - 2009 interim results DoH & PASA Publish report on Success of BIOQUELL System in Showcase Hospital Programme Results of AGM Proxy Voting May 2009 AGM Results Notice Results of AGM Proxy voting Notice of Annual General Meeting Interim Management Statement Directors’ exercise of options and acquisition of Shares Grant of options to Directors Annual Report 2008 BIOQUELL delivers strong growth in pre-tax profit and cash in 2008 BIOQUELL takes top prize at the Department of Health HCAI Technology Innovation Summit 2008 Interim Results Purchase of ordinary shares Directors’ dealings – purchase of Shares Results of AGM Proxy voting, Results of EGM Proxy voting, Results of Separate Class Meeting Proxy voting BIOQUELL PLC EGM - Cancellation of Share Premium Account Adoption of New Articles of Association & Amendment of the BIOQUELL Share Option Schemes PLC PRESS RELEASE: 2007 Preliminary Results PRESS RELEASE: Award of Joint Material Decontamination System Sub-Contract |
TO: COMPANIES ANNOUNCEMENT OFFICE 28 April 2009 BIOQUELL PLC Directors’ exercise of options and acquisition of Shares Nick Adams, Chief Executive of BIOQUELL PLC (“BIOQUELL” or the “Company”) and Mark Bodeker, Chief Operating Officer, each had 80,000 options over BIOQUELL ordinary shares (“Shares”) with an exercise price of 107.5p which expire on 29 April, 2009 (the “2002 Options”). BIOQUELL has provisions within its executive share option schemes relating to ‘Share Appreciation Rights’ (the “SARS Provisions”) whereby, in summary, the Board of BIOQUELL (the “Board”) is able to satisfy the exercise of options by issuing new Shares, calculated by reference to the prevailing market Share price, equivalent to the uplift in value associated with the options. The Board has decided that the SARS Provisions should be used on the exercise of the 2002 Options in order to, among other things, reduce significantly the dilution associated with such exercise. Accordingly, on 27 April 2009, Mr Adams informed the Company that he had exercised 80,000 options over Shares with an exercise price of 107.5p and pursuant to the SARS Provisions a total of 4,561 new Shares were issued to Mr Adams. Mr Adams now holds 724,561 Shares representing approximately 1.7% of the issued ordinary Share capital. On 27 April 2009, Mr Bodeker informed the Company that he had exercised 80,000 options over Shares with an exercise price of 107.5p and pursuant to the SARS Provisions a total of 4,561 new Shares were issued to Mr Bodeker. Mr Bodeker now holds 38,928 Shares. - Ends - Enquiries: Mark Bodeker BIOQUELL PLC 01264 835 900 
|
